Next Article in Journal
Molecular Characterization of a Novel Splicing Mutation Underlying Mucopolysaccharidosis (MPS) Type VI—Indirect Proof of Principle on Its Pathogenicity
Next Article in Special Issue
Assessing the Costs of Screening for Ovarian Cancer in the United States: An Evolving Analysis
Previous Article in Journal
Quantification of Endogenous Brain Tissue Displacement Imaging by Radiofrequency Ultrasound
Previous Article in Special Issue
Mucinous Cancer of the Ovary: Overview and Current Status
Open AccessArticle

Disease-Specific Survival of Type I and Type II Epithelial Ovarian Cancers—Stage Challenges Categorical Assignments of Indolence & Aggressiveness

1
Department of Obstetrics & Gynecology, University of Kentucky, Lexington, KY 40536, USA
2
Division of Gynecologic Oncology, Markey Cancer Center, Lexington, KY 40536, USA
3
Denison University, Granville, OH 43023, USA
4
Department of Obstetrics & Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, NH 43023, USA
5
Division of Cancer Biostatistics, College of Public Health & Biostatistics Shared Resource Facility, Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA
6
Department of Pathology and the Markey Cancer Center, Lexington, KY 40536, USA
*
Author to whom correspondence should be addressed.
Diagnostics 2020, 10(2), 56; https://doi.org/10.3390/diagnostics10020056
Received: 31 December 2019 / Revised: 15 January 2020 / Accepted: 17 January 2020 / Published: 21 January 2020
(This article belongs to the Special Issue Ovarian Cancer: Characteristics, Screening, Diagnosis and Treatment)
Epithelial ovarian cancers (EOC) consist of several sub-types based on histology, clinical, molecular and epidemiological features that are termed “histo-types”, which can be categorized into less aggressive Type I and more aggressive Type II malignancies. This investigation evaluated the disease-specific survival (DSS) of women with Type I and II EOC using histo-type, grade, and stage. A total of 47,789 EOC cases were identified in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) data. Survival analysis and log rank test were performed to identify a 2-tiered classification (grade 1 vs. grade 2 & 3) for serous EOC. DSS of early stage serous EOC for grade 2 was significantly different from grade 3 indicating that a 2-tier classification for serous EOC applied only to late stage. DSS of Type I EOC was much better than Type II. However, DSS was 33–52% lower with late stage Type I than with early stage Type I indicating that Type I ovarian cancers should not be considered indolent. Early stage Type II EOC had much better DSS than late stage Type II stressing that stage has a large role in survival of both Type I and II EOC. View Full-Text
Keywords: epithelial ovarian cancer; survival; Type I & Type II; histo-types; grade; stage epithelial ovarian cancer; survival; Type I & Type II; histo-types; grade; stage
Show Figures

Figure 1

MDPI and ACS Style

Pavlik, E.J.; Smith, C.; Dennis, T.S.; Harvey, E.; Huang, B.; Chen, Q.; West Piecoro, D.; Burgess, B.T.; McDowell, A.; Gorski, J.; Baldwin, L.A.; Miller, R.W.; DeSimone, C.P.; Dietrich, C., III; Gallion, H.H.; Ueland, F.R.; van Nagell, J.R., Jr. Disease-Specific Survival of Type I and Type II Epithelial Ovarian Cancers—Stage Challenges Categorical Assignments of Indolence & Aggressiveness. Diagnostics 2020, 10, 56.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop